Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 28;17:2593–2611. doi: 10.2147/DDDT.S421300

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Zhang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Identification of the Mechanisms of Cinnamomi Ramulus (CR) and Tripterygii Radix (TR) in the Treatment of Psoriasis. (A) Representative photographs of the back of each group of mice. (B) Scab/Erythema/Infiltrate/psoriasis area severity index (PASI) score of each group for day1, day2, day3, day4, day4, day5, day6 and day7. Left: TR, Right: CR. (C) Skin lesions of each group were stained with HE (Magnification × 10, scale bars = 250 µm; Magnification × 40, scale bars = 50 µm). (D) Skin lesions of each group were stained with NFKB2, TRPV3, YAP1 (Magnification × 10, scale bars = 250 µm; Magnification × 40, scale bars = 50 µm). See also Figure S10. (E) Differences of NFKB2, TRPV3, YAP1 immunohistochemical staining intensity among nine groups as assessed by H-score (n = 4). One-way ANOVA was conducted. *P < 0.05, **P < 0.01, ***P < 0.001. Model, imiquimod; Low dose, 0.585 g/kg/day; medium dose, 1.17 g/kg/day; high dose, 2.34 g/kg/day. See also Figure S11.